Results 11 to 20 of about 38,006 (217)

Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes

International Journal of Cardiology: Heart & Vasculature, 2022
Background: Recent clinical trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors have beneficial effects on renal function in heart failure patients. This study confirmed the renoprotective effect of treatment with SGLT2 inhibitors in
Go Yokouchi, Takeshi Horio, Naoki Matsumoto, Kohei Fukuda, Ryutaro Yoshimura, Ryosuke Fujiwara, Yujiro Matsuoka, Yuya Sakamoto, Yoshio Iwashima, Yoshiyuki Oshiro, Kohei Fujimoto, Noriaki Kasayuki   +11 more
doaj   +1 more source

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus

Cardiovascular Diabetology, 2022
Background There have been scarce data comparing cardiovascular outcomes between individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the subsequent cardiovascular risk between individual SGLT2 inhibitors. Methods We analyzed
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro   +15 more
doaj   +1 more source

The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study

Medicines, 2022
Background: The incidence and risk of urinary tract infection (UTI) in patients with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 (SGLT2) inhibitors are still controversial.
Suriyon Uitrakul, Krittika Aksonnam, Pimchanok Srivichai, Sorawit Wicheannarat, Supatcha Incomenoy   +4 more
doaj   +1 more source

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology

Frontiers in Cardiovascular Medicine, 2022
PurposeSodium-glucose cotransporter 2 (SGLT2) inhibitors have cardiorenal protective effects regardless of whether they are combined with type 2 diabetes mellitus, but their specific pharmacological mechanisms remain undetermined.Materials and MethodsWe ...
Anzhu Wang, Anzhu Wang, Zhendong Li, Sun Zhuo, Feng Gao, Feng Gao, Hongwei Zhang, Hongwei Zhang, Zhibo Zhang, Zhibo Zhang, Gaocan Ren, Gaocan Ren, Xiaochang Ma, Xiaochang Ma   +13 more
doaj   +1 more source

Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials

Therapeutic Advances in Chronic Disease, 2022
Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce serum urate in patients with type 2 diabetes mellitus. To evaluate if this effect applies to both patients with and without diabetes, we conducted a systematic review
Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, Yao Neng Teo, Nicholas L. X. Syn, Ray Meng See, Caitlin Fern Wee, Elliot Yeung Chong, Chi-Hang Lee, Mark Y. Chan, Tiong-Cheng Yeo, Raymond C. C. Wong, Ping Chai, Ching-Hui Sia   +13 more
doaj   +1 more source

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

Medicina, 2023
There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys’ sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose ...
Munteanu Madalina Andreea, Swarnkar Surabhi, Popescu Razvan-Ionut, Ciobotaru Lucia, Nicolae Camelia, Tufanoiu Emil, Nanea Ioan Tiberiu   +6 more
doaj   +1 more source

Sodium–Glucose Cotransporter 2 Inhibitors Work as a “Regulator” of Autophagic Activity in Overnutrition Diseases

Frontiers in Pharmacology, 2021
Several large clinical trials have shown renal and cardioprotective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors in diabetes patients, and the protective mechanisms need to be elucidated.
Kazuhiko Fukushima, Shinji Kitamura, Kenji Tsuji, Jun Wada   +3 more
doaj   +1 more source

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2021
Background Using real-world data, cardiovascular safety was investigated in metformin users newly starting sodium glucose cotransporter 2 (SGLT2) inhibitors compared with other glucose-lowering drugs in Korea.
Ja Young Jeon, Kyoung Hwa Ha, Dae Jung Kim   +2 more
doaj   +1 more source

Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis [PDF]

Endocrinology and Metabolism, 2023
When sodium-glucose cotransporter-2 (SGLT2) inhibitors were first introduced a decade ago, no one expected them to have substantial effects beyond their known glucose-lowering effects, until the emergence of evidence of their robust renal and ...
Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
doaj   +1 more source

Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis

Scientific Reports, 2021
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown impressive effects in reducing major vascular events in several randomized controlled trials (RCTs).
Wen-Hsuan Tsai, Shih-Ming Chuang, Sung-Chen Liu, Chun-Chuan Lee, Ming-Nan Chien, Ching-Hsiang Leung, Shu-Jung Liu, Hong-Mou Shih   +7 more
doaj   +1 more source